Trials that use: Log-rank test
New to this method? Read the tutorial →
220 results
- IMpassion131Independent statistical analysis of IMpassion131, a randomized phase 3 trial of atezolizumab plus paclitaxel versus placebo plus paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer.
- IMpower010Independent statistical analysis of IMpower010, the randomized phase 3 trial of atezolizumab versus best supportive care following chemotherapy in non-small cell lung cancer, including disease-free survival, time-to-event methodology, confidence intervals, and interpretation.
- IMpower132Independent statistical analysis of IMpower132, a phase 3 randomized trial of atezolizumab plus platinum-pemetrexed versus platinum-pemetrexed in chemotherapy-naive participants with stage IV non-squamous non-small cell lung cancer.
- IMpower133Independent statistical analysis of IMpower133 (NCT02763579), a randomized phase 3 trial of atezolizumab plus carboplatin and etoposide versus placebo plus carboplatin and etoposide in untreated extensive-stage small cell lung cancer.
- IMvigor010Independent statistical analysis of IMvigor010, the randomized phase 3 study of atezolizumab versus observation as adjuvant therapy after surgical resection for high-risk muscle-invasive urothelial carcinoma.
- IMvigor130Independent statistical analysis of IMvigor130, a randomized phase 3 trial of atezolizumab with platinum-based chemotherapy or as monotherapy in untreated locally advanced or metastatic urothelial carcinoma.
- IMvigor211Independent statistical analysis of the phase 3 IMvigor211 trial of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer, including overall survival, hazard ratios, confidence intervals, and…
- INAVO120Independent statistical analysis of the INAVO120 trial of inavolisib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.
- INBUILDIndependent statistical analysis of the INBUILD phase 3 trial of nintedanib in patients with progressive fibrosing interstitial lung disease, including FVC decline, longitudinal modeling, time-to-event endpoints, logistic regression, safety, and interpretation.
- iPrExIndependent statistical analysis of the randomized phase 3 iPrEx trial of daily TDF/FTC versus placebo for HIV prevention in men, including primary efficacy and safety endpoints, secondary analyses, statistical methods, and interpretation.
- JAVELIN Bladder 100A detailed statistical analysis of the randomized phase 3 JAVELIN Bladder 100 trial of avelumab plus best supportive care versus best supportive care in patients with urothelial cancer, including trial design, time-to-event…
- JAVELIN Head and Neck 100Independent statistical analysis of JAVELIN Head and Neck 100, a randomized phase 3 trial comparing avelumab plus standard of care chemoradiotherapy with placebo plus standard of care chemoradiotherapy in squamous cell carcinoma…
- JAVELIN Ovarian 100Independent statistical analysis of JAVELIN Ovarian 100, the phase 3 trial of avelumab-based strategies in previously untreated epithelial ovarian cancer, including progression-free survival, overall survival, statistical methodology, safety, and interpretation.
- JAVELIN Renal 101Complete statistical analysis of JAVELIN Renal 101, the randomized phase 3 trial of avelumab plus axitinib versus sunitinib in advanced renal cell cancer, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing,…
- KATHERINEIndependent statistical analysis of KATHERINE, the randomized phase 3 trial of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer and residual tumor following preoperative therapy.
- KEYNOTE-006Independent statistical analysis of KEYNOTE-006, a randomized phase 3 trial comparing two pembrolizumab dosing schedules with ipilimumab in participants with advanced melanoma.
- KEYNOTE-010Independent statistical analysis of KEYNOTE-010, including its randomized phase 2/3 design, overall survival, progression-free survival, response, safety, statistical methods, and interpretation.
- KEYNOTE-040Independent statistical analysis of KEYNOTE-040, a randomized phase 3 trial of pembrolizumab versus standard treatment for recurrent or metastatic head and neck squamous cell cancer, including overall survival, progression-free survival, response, statistical…
- KEYNOTE-177Independent statistical analysis of KEYNOTE-177, the randomized phase 3 trial of pembrolizumab versus standard of care in participants with MSI-H or dMMR stage IV colorectal carcinoma, covering PFS, overall survival, response, statistical…
- KEYNOTE-189Independent statistical analysis of KEYNOTE-189 (NCT02578680), a randomized phase 3 trial evaluating pembrolizumab with pemetrexed-platinum chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
- KEYNOTE-240Independent statistical analysis of KEYNOTE-240, a randomized phase 3 trial of pembrolizumab plus best supportive care versus placebo plus best supportive care in previously systemically treated advanced hepatocellular carcinoma.
- KEYNOTE-355Independent statistical analysis of KEYNOTE-355, evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- KEYNOTE-426Independent statistical analysis of KEYNOTE-426, the randomized phase 3 trial of pembrolizumab plus axitinib versus sunitinib monotherapy in renal cell carcinoma, including primary survival endpoints, response outcomes, statistical methodology, and interpretation.
- KEYNOTE-564Independent statistical analysis of KEYNOTE-564, a randomized phase 3 trial of pembrolizumab versus placebo in the adjuvant treatment of renal cell carcinoma after nephrectomy, including disease-free survival, trial design, statistical methodology, and…
- KEYNOTE-598Independent statistical analysis of KEYNOTE-598, a randomized phase 3 trial of pembrolizumab with ipilimumab versus pembrolizumab with placebo in untreated metastatic non-small cell lung cancer. Includes overall survival, progression-free survival, response, quality…
- KEYNOTE-671Independent statistical analysis of KEYNOTE-671, a randomized phase 3 trial of pembrolizumab with platinum-doublet chemotherapy as neoadjuvant/adjuvant therapy for resectable stage II, IIIA, and resectable IIIB non-small cell lung cancer.
- KEYNOTE-716Independent statistical analysis of KEYNOTE-716, a randomized phase 3 trial of pembrolizumab versus placebo in resected high-risk stage II melanoma, including trial design, recurrence-free survival, safety, statistical methodology, and interpretation.
- KEYNOTE-775Independent statistical analysis of KEYNOTE-775, evaluating lenvatinib plus pembrolizumab versus treatment of physician's choice in advanced endometrial cancer, with detailed interpretation of PFS, OS, response, quality-of-life, and statistical methods.
- KEYNOTE-811Independent statistical analysis of KEYNOTE-811, a randomized phase 3 trial of pembrolizumab plus trastuzumab and chemotherapy versus standard of care in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
- KEYNOTE-859Independent statistical analysis of KEYNOTE-859, a randomized phase 3 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric or gastroesophageal junction adenocarcinoma, including overall survival, progression-free survival, objective response rate,…
- KEYNOTE-966Independent statistical analysis of KEYNOTE-966, evaluating pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin for first-line advanced and/or unresectable biliary tract carcinoma.
- KEYNOTE-A18Independent statistical analysis of KEYNOTE-A18 (NCT04221945), a randomized phase 3 trial of chemoradiotherapy with or without pembrolizumab in locally advanced cervical cancer, including primary time-to-event results, secondary endpoints, cLDA, stratified analysis, and…
- KRYSTAL-12Independent statistical analysis of KRYSTAL-12, the phase 3 randomized trial of adagrasib versus docetaxel in patients with advanced non-small cell lung cancer with a KRAS G12C mutation.
- LEAP-002Independent statistical analysis of LEAP-002, the randomized phase 3 trial of lenvatinib plus pembrolizumab versus lenvatinib plus placebo as first-line therapy in advanced hepatocellular carcinoma.
- LUX-Lung 6Independent statistical analysis of LUX-Lung 6, the randomized phase 3 trial comparing afatinib with gemcitabine-cisplatin chemotherapy in first-line non-small cell lung cancer. Includes progression-free survival, response, overall survival, quality-of-life endpoints, statistical methods,…
- LUX-Lung 7Independent statistical analysis of LUX-Lung 7, the randomized phase 2 trial comparing afatinib with gefitinib in first-line EGFR mutation-positive lung adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- LUX-Lung 8Independent statistical analysis of LUX-Lung 8, the phase 3 randomized trial of afatinib versus erlotinib in squamous cell lung cancer after at least one prior platinum-based chemotherapy. Includes progression-free survival, overall survival,…
- MA.17Independent statistical analysis of MA.17, a randomized phase 3 trial evaluating letrozole versus placebo in women with breast cancer who had received 5 years of aromatase inhibitor therapy, including disease-free survival, overall…
- MAGNITUDEIndependent statistical analysis of the phase 3 MAGNITUDE trial of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in castration-resistant prostate cancer, including rPFS, hazard ratios, confidence…
- MARIPOSAAn independent statistical analysis of the MARIPOSA phase 3 trial of amivantamab plus lazertinib versus osimertinib in locally advanced or metastatic non-small cell lung cancer, including trial design, progression-free survival methodology, results,…
- METEORIndependent statistical analysis of the METEOR phase 3 trial of cabozantinib versus everolimus in metastatic renal cell carcinoma, including progression-free survival, overall survival, objective response rate, trial design, and statistical methodology.
- MIRASOLIndependent statistical analysis of the MIRASOL phase 3 trial of mirvetuximab soravtansine versus investigator's choice chemotherapy in platinum-resistant advanced ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.
- ML18147Independent statistical analysis of ML18147, a randomized phase 3 trial of bevacizumab plus chemotherapy in metastatic colorectal cancer, including overall survival, progression-free survival, response rate, statistical methodology, safety, and interpretation.
- MONALEESA-2Complete statistical analysis of MONALEESA-2, the randomized phase 3 trial of ribociclib plus letrozole versus placebo plus letrozole in postmenopausal women with advanced or metastatic breast cancer.
- MONALEESA-3Independent statistical analysis of MONALEESA-3 (NCT02422615), a randomized phase 3 trial of ribociclib plus fulvestrant versus placebo plus fulvestrant in advanced breast cancer.
- MONALEESA-7Independent statistical analysis of MONALEESA-7, a randomized phase 3 trial of ribociclib plus endocrine therapy and goserelin versus placebo plus endocrine therapy and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced…
- MONARCH 2Independent statistical analysis of the MONARCH 2 phase 3 trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant, including trial design, progression-free survival, statistical methodology, interpretation, limitations, and safety.
- MONARCH 3Independent statistical analysis of the phase 3 MONARCH 3 trial of abemaciclib plus a nonsteroidal aromatase inhibitor in postmenopausal women with breast cancer, including progression-free survival, response, health-status outcomes, methodology, safety, and…
- MONARCH EIndependent statistical analysis of MONARCH E, the randomized phase 3 trial of abemaciclib plus standard adjuvant endocrine therapy versus endocrine therapy in breast cancer, including invasive disease-free survival, distant relapse-free survival, trial…
- NALAIndependent statistical analysis of NALA, a randomized phase 3 trial of neratinib plus capecitabine versus lapatinib plus capecitabine in HER2+ metastatic breast cancer after two or more prior HER2-directed regimens.